Julio Rosenstock
University of Texas Southwestern Medical Center
Internal medicineEndocrinologyRandomized controlled trialAdverse effectPlaceboType 2 diabetesPostprandialInsulinInsulin glargineMetforminGlycemicHypoglycemiaType 1 diabetesType 2 Diabetes MellitusWeight lossDiabetes mellitusMedicineGastroenterology
441Publications
103H-index
27.8kCitations
Publications 452
Newest
Basal insulin treatment is indispensable for patients with type 1 diabetes and often required by many with type 2 diabetes. Incremental advances lengthening the duration of action of insulin analogs and reducing pharmacodynamic variability have resulted in truly once-daily, long-acting basal insulin analogs. In the quest for better basal insulins to facilitate improvements in glycemic control and long-term outcomes, the driving need is to remove barriers delaying timely initiation of basal insul...
Source
#1Carolyn S.P. Lam (NUS: National University of Singapore)H-Index: 80
#2Chinthanie Ramasundarahettige (Population Health Research Institute)H-Index: 9
Last. Hertzel C. Gerstein (Population Health Research Institute)H-Index: 115
view all 12 authors...
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) both reduce cardiovascular (CV) events among patients with type 2 diabetes. However, no CV outcome trial has evaluated the long-term effects of their combined use. The AMPLITUDE-O trial reported that once weekly injections of the GLP-1 RA efpeglenatide (vs. placebo) reduced major adverse cardiovascular events (MACE); MACE, coronary revascularization or unstable angina hospital...
Source
Source
I thank Dr. Marathe and coauthors, who are part of the superb team of Michael Horowitz and Karen Jones, world-renowned top experts in gastric emptying (1), for recognizing the clinical value of our albiglutide switch study (HARMONY 8), which provided proof of concept for the benefits of using a weekly glucagon-like peptide 1 receptor agonist (GLP-1RA) to simplify an intensive multiple-insulin regimen in patients with long-standing type 2 diabetes previously on basal-bolus insulin (2). We clearly...
Source
#1Ronald GoldenbergH-Index: 24
#2Vanita R. ArodaH-Index: 35
Last. Melanie J. DaviesH-Index: 98
view all 8 authors...
Source
#1Stefano Del Prato (UniPi: University of Pisa)H-Index: 72
#2Steven E. Kahn (UW: University of Washington)H-Index: 127
Last. Robert J. Heine (Eli Lilly and Company)H-Index: 22
view all 206 authors...
Summary null null Background null We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications. null null null Methods null This open-label, parallel-group, phase 3 study was done in 187 sites in 14 countries on five continents. Eligible participants, aged 18 years or...
Source
#1Melanie J. Davies (University of Leicester)H-Index: 98
#2Julio RosenstockH-Index: 103
Last. Neil SkolnikH-Index: 8
view all 9 authors...
AIMS To assess the efficacy and safety of iGlarLixi (the titratable fixed-ratio combination of insulin glargine 100 U/mL [iGlar] plus lixisenatide [Lixi]), in adults with type 2 diabetes (T2D) with glycated haemoglobin (HbA1c) levels ≥8% (≥64 mmol/mol). MATERIALS AND METHODS The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD). This exploratory analysis evaluated the LixiLan-O subgr...
Source
#1David Z.I. Cherney (UHN: University Health Network)H-Index: 47
#2Petter Bjornstad (Anschutz Medical Campus)H-Index: 27
Last. Nima Soleymanlou (Boehringer Ingelheim)H-Index: 12
view all 7 authors...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower risk of cardiovascular and kidney events in people with type 2 diabetes. In the empagliflozin in type 1 diabetes clinical program (Empagliflozin as Adjunctive to inSulin thErapy [EASE]), glycemic control, body weight, and BP improved with
Source
#1David Z.I. Cherney (U of T: University of Toronto)H-Index: 47
#2Ele FerranniniH-Index: 101
Last. Rajiv Agarwal (IU: Indiana University)H-Index: 85
view all 9 authors...
AIMS To assess the efficacy and safety of sotagliflozin, a dual inhibitor of sodium-glucose cotransporter-1 and -2, in adults with type 2 diabetes (T2D) and stage 4 chronic kidney disease (CKD4). MATERIALS AND METHODS This 52-week, phase 3, randomized (1:1:1), placebo-controlled trial evaluated sotagliflozin 200 mg and sotagliflozin 400 mg once daily in 277 patients with T2D and estimated glomerular filtration rate (eGFR) 15 to 30 mL/min/1.73 m2 . The primary endpoint was glycated haemoglobin (H...
Source
#1Naveed Sattar (BHF: British Heart Foundation)H-Index: 174
#2Matthew M.Y. Lee (BHF: British Heart Foundation)H-Index: 11
Last. Richard E. Pratley (Translational Research Institute)H-Index: 23
view all 12 authors...
Summary null null Background null GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes. null null null Methods null We did a meta-ana...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.